**ASSESSING THE RELATIONSHIP BETWEEN MONOALLELIC *PARK2* MUTATIONS AND PARKINSON’S RISK**

**SUPPLEMENTARY INFORMATION**

Supplementary Table 1: Meta-analyses of heterozygous *PARK2* mutation carriers in studies that investigated and excluded PD patients with biallelic *PARK2* mutations.

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
|  | Study | PD | Controls | OR (95% CI) |
| Carrier | Non-carrier | Carrier | Non-carrier |
|  | Benitez et al. 2016 | 3 | 466 | 2 | 335 | 1.08 (0.18-6.49) |
|  | Brooks et al. 2009 | 9 | 241 | 5 | 271 | 2.02 (0.67-6.12) |
|  | Clark et al. 2006 | 5 | 95 | 0 | 105 | 12.15 (0.66-222.68) |
|  | Hertz et al. 2006 | 5 | 82 | 0 | 50 | 6.73 (0.37-124.37) |
|  | Klein et al. 2005 | 1 | 62 | 0 | 100 | 4.82 (0.19-120.27) |
|  | Lesage et al. 2008 | 9 | 150 | 0 | 170 | 21.35 (1.24-372.96) |
|  | Lincoln et al. 2003 | 9 | 304 | 6 | 186 | 0.92 (0.32-2.62) |
|  | Spataro et al. 2017 | 4 | 240 | 1 | 144 | 2.40 (0.27-21.68) |
|  | Wiley et al. 2004 | 5 | 96 | 0 | 45 | 5.19 (0.28-95.82) |
|  | **Pooled** | **50** | **1,736** | **9** | **1,406** | **2.00 (1.10-3.62)** |

Key: Carrier, number of samples harbouring mutation, CI, confidence intervals; OR, odds ratio; *PARK2*, *Parkin* (NM\_013988 and NM\_004562); PD, Parkinson’s cases.

Supplementary Table 2: Meta-analyses of heterozygous *PARK2* variant carriers, excluding p.R275W (c.823C>T, rs34424986).

|  |  |  |  |
| --- | --- | --- | --- |
| Study | PD | Controls | OR (95% CI) |
| Carrier | Non-carrier | Carrier | Non-carrier |
| Bandres-Ciga et al. 2016 | 1 | 125 | 0 | 97 | 2.33 (0.09-57.84) |
| Benitez et al. 2016 | 1 | 468 | 0 | 337 | 2.16 (0.09-53.21) |
| Bras et al. 2008 | 4 | 55 | 0 | 126 | 20.51 (1.09-387.54) |
| Brooks et al. 2009 | 8 | 242 | 4 | 272 | 2.25 (0.67-7.56) |
| Clark et al. 2006 | 4 | 96 | 0 | 105 | 9.84 (0.54-185.15) |
| Erer et al. 2016 | 2 | 48 | 0 | 47 | 4.90 (0.23-104.71) |
| Hertz et al. 2006 | 5 | 82 | 0 | 50 | 6.73 (0.37-124.37) |
| Huttenlocher et al. 2015 | 22 | 1,391 | 965 | 103,355 | 1.69 (1.11-2.59) |
| Kann et al. 2002 | 6 | 101 | 0 | 75 | 9.67 (0.54-174.31) |
| Kay et al. 2010 | 17 | 1,920 | 13 | 1,629 | 1.11 (0.54-2.29) |
| Lesage et al. 2008 | 5 | 154 | 0 | 170 | 12.14 (0.67-221.33) |
| Lincoln et al. 2003 | 5 | 306 | 3 | 189 | 1.03 (0.24-4.36) |
| Macedo et al. 2009 | 5 | 175 | 0 | 363 | 22.78 (1.25-414.34) |
| Moura et al. 2013 | 2 | 133 | 0 | 200 | 7.51 (0.36-157.65) |
| Pankratz et al. 2011 | 10 | 386 | 8 | 848 | 2.75 (1.08-7.01) |
| Schlitter et al. 2006\* | 1 | 93 | 0 | 149 | 4.80 (0.19-118.98) |
| Simon-Sanchez et al. 2008 | 3 | 269 | 4 | 271 | 0.76 (0.17-3.41) |
| Sironi et al. 2008 | 5 | 133 | 0 | 50 | 4.16 (0.23-76.62) |
| Spataro et al. 2017 | 10 | 232 | 1 | 144 | 2.40 (0.27-21.68) |
| Wiley et al. 2004 | 2 | 99 | 0 | 45 | 2.29 (0.11-48.60) |
| PPMI | 1 | 384 | 0 | 179 | 1.40 (0.06-34.55) |
| UKBiobank (Exome) | 1 | 113 | 140 | 38,123 | 2.41 (0.33-17.38) |
| Lubbe et al. (IPDGC, Exome) | 7 | 1,224 | 1 | 472 | 2.70 (0.33-21.99) |
| Lubbe et al. (IPDGC, NeuroX) | 17 | 6,535 | 15 | 5,678 | 0.99 (0.49-1.97) |
| Lubbe et al. (IPDGC, Reseq)  | 12 | 3,059 | 4 | 2,158 | 2.12 (0.68-6.57) |
| **Pooled** | **150** | **17,831** | **1,158** | **155,132** | **1.76 (1.37-2.28)** |

Key: CI, confidence intervals; IPDGC, International Parkinson’s disease Genomics Consortium; *PARK2*, *Parkin* (NM\_013988 and NM\_004562); OR, odds ratio; PPMI, Parkinson’s Progression Markers Initiative; Reseq, Resequencing; \*German samples only.

Supplementary Table 3: Meta-analyses of heterozygous *PARK2* mutation carriers, stratified by type of mutation.

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
|  | Study | PD | Controls | OR (95% CI) |
| Carrier | Non-carrier | Carrier | Non-carrier |
| Heterozygous *PARK2* SNVs |  |  |  |  |  |
|  | Bandres-Ciga et al. 2016 | 1 | 125 | 0 | 97 | 2.33 (0.09-57.84) |
|  | Benitez et al. 2016 | 3 | 466 | 2 | 335 | 1.08 (0.18-6.49) |
|  | Bras et al. 2008 | 1 | 58 | 0 | 126 | 6.49 (0.26-161.65) |
|  | Brooks et al. 2009 | 2 | 242 | 2 | 274 | 1.13 (0.16-8.10) |
|  | Clark et al. 2006 | 3 | 97 | 0 | 105 | 7.57 (0.39-148.52) |
|  | Erer et al. 2016 | 2 | 48 | 0 | 47 | 4.90 (0.23-104.71) |
|  | Hertz et al. 2006 | 1 | 86 | 0 | 50 | 1.75 (0.07-43.81) |
|  | Kann et al. 2002 | 3 | 104 | 0 | 75 | 5.06 (0.26-99.36) |
|  | Klein et al. 2005 | 1 | 62 | 0 | 100 | 4.82 (0.19-120.27) |
|  | Lesage et al. 2008 | 4 | 155 | 0 | 170 | 9.87 (0.53-184.77) |
|  | Lincoln et al. 2003 | 7 | 305 | 5 | 187 | 0.86 (0.27-2.74) |
|  | Macedo et al. 2009 | 2 | 178 | 0 | 363 | 10.18 (0.49-213.21) |
|  | Moura et al. 2013 | 2 | 133 | 0 | 200 | 7.51 (0.36-157.65) |
|  | Schlitter et al. 2006\* | 1 | 93 | 0 | 149 | 4.80 (0.19-118.98) |
|  | Sironi et al. 2008 | 2 | 136 | 0 | 50 | 1.85 (0.09-39.20) |
|  | Spataro et al. 2017 | 4 | 240 | 1 | 144 | 2.40 (0.27-21.68) |
|  | Wiley et al. 2004 | 3 | 98 | 0 | 45 | 3.23 (0.16-63.91) |
|  | PPMI | 4 | 381 | 0 | 179 | 4.24 (0.23-79.08) |
|  | UKBiobank (Genotype) | 15 | 1,413 | 2,548 | 309,550 | 1.29 (0.77-2.15) |
|  | UKBiobank (Exome) | 1 | 113 | 467 | 37,796 | 0.72 (0.10-5.14) |
|  | Lubbe et al. (IPDGC, Exome) | 23 | 1,208 | 5 | 468 | 1.78 (0.67-4.72) |
|  | Lubbe et al. (IPDGC, NeuroX) | 55 | 6,497 | 33 | 5,660 | 1.45 (0.94-2.24) |
|  | Lubbe et al. (IPDGC, Reseq) | 36 | 3,035 | 16 | 2,146 | 1.59 (0.88-2.87) |
|  | **Pooled** | **176** | **15,273** | **3,079** | **358,316** | **1.56 (1.22-2.00)** |
| Heterozygous *PARK2* CNVs |  |  |  |  |  |
|  | Bras et al. 2008 | 3 | 56 | 0 | 126 | 15.67 (0.80-308.48) |
|  | Brooks et al. 2009 | 7 | 243 | 3 | 273 | 2.62 (0.67-10.25) |
|  | Clark et al. 2006 | 2 | 98 | 0 | 105 | 5.36 (0.25-112.94) |
|  | Hertz et al. 2006 | 4 | 82 | 0 | 50 | 5.51 (0.29-104.49) |
|  | Huttenlocher et al. 2015 | 22 | 1,391 | 965 | 103,355 | 1.69 (1.11-2.59) |
|  | Kann et al. 2002 | 3 | 104 | 0 | 75 | 5.06 (0.26-99.36) |
|  | Kay et al. 2010 | 17 | 1,920 | 13 | 1,629 | 1.11 (0.54-2.29) |
|  | Lesage et al. 2008 | 5 | 154 | 0 | 170 | 12.14 (0.67-221.33) |
|  | Lincoln et al. 2003 | 2 | 309 | 1 | 191 | 1.24 (0.11-13.73) |
|  | Macedo et al. 2009 | 3 | 177 | 0 | 363 | 14.34 (0.74-279.04) |
|  | Pankratz et al. 2011 | 10 | 386 | 8 | 848 | 2.75 (1.08-7.01) |
|  | Simon-Sanchez et al. 2008 | 3 | 269 | 4 | 271 | 0.76 (0.17-3.41) |
|  | Sironi et al. 2008 | 3 | 135 | 0 | 50 | 2.61 (0.13-51.40) |
|  | Wiley et al. 2004 | 2 | 99 | 0 | 45 | 2.29 (0.11-48.60) |
|  | Lubbe et al. (IPDGC, NeuroX) | 11 | 6,541 | 4 | 5,689 | 2.39 (0.76-7.52) |
|  | **Pooled** | **97** | **11,964** | **998** | **113,240** | **1.85 (1.38-2.50)** |

Key: Carrier, number of samples harbouring mutation, CI, confidence intervals; CNV, copy number variant; IPDGC, International Parkinson’s disease Genomics Consortium; OR, odds ratio; *PARK2*, *Parkin* (NM\_013988 and NM\_004562); PD, Parkinson’s cases; PPMI, Parkinson’s Progression Markers Initiative; Reseq, Resequencing; SNV, single nucleotide variant; \* German samples.

Supplementary Table 4: List of *PARK2* mutations that were considered to be pathogenic.

|  |
| --- |
| Mutation |
| PARK2 ex10-12 del |
| PARK2 ex10-12 dup |
| PARK2 ex10 del |
| PARK2 ex10 dup |
| PARK2 ex11 del |
| PARK2 ex11 dup |
| PARK2 ex12 dup |
| PARK2 ex1-4 del |
| PARK2 ex1 del |
| PARK2 ex1 dup |
| PARK2 ex2-12 dup |
| PARK2 ex2-3 del |
| PARK2 ex2-3 dup |
| PARK2 ex2-4 del |
| PARK2 ex2-4 dup |
| PARK2 ex2-4 trip |
| PARK2 ex2-5 del |
| PARK2 ex2 del |
| PARK2 ex2 dup |
| PARK2 ex2 trip |
| PARK2 ex3-4 del |
| PARK2 ex3-4 dup |
| PARK2 ex3-5 del |
| PARK2 ex3-6 del |
| PARK2 ex3-7 del |
| PARK2 ex3-9 del |
| PARK2 ex3 del |
| PARK2 ex3 dup |
| PARK2 ex4-5 del |
| PARK2 ex4-6 del |
| PARK2 ex4-7 del |
| PARK2 ex4 del |
| PARK2 ex4 dup |
| PARK2 ex5-12 del |
| PARK2 ex5-6 del |
| PARK2 ex5-7 del |
| PARK2 ex5-8 dup |
| PARK2 ex5-9 dup |
| PARK2 ex5 del |
| PARK2 ex5 dup |
| PARK2 ex6-7 del |
| PARK2 ex6-8 dup |
| PARK2 ex6 del |
| PARK2 ex6 dup |
| PARK2 ex7-8 del |
| PARK2 ex7-9 del |
| PARK2 ex7 del |
| PARK2 ex7 dup |
| PARK2 ex8-10 del |
| PARK2 ex8-11 del |
| PARK2 ex8-9 del |
| PARK2 ex8 del |
| PARK2 ex8 dup |
| PARK2 ex9 del |
| PARK2 ex9 dup |
| PARK2 partial ex4 del |
| PARK2 promoter + ex1 del |
| PARK2 Met1Leu |
| PARK2 c.7+1G>A |
| PARK2 c.8-39G>A |
| PARK2 Ala31Asp |
| PARK2 Arg33Stop |
| PARK2 Arg33Gln |
| PARK2 Gln34fs |
| PARK2 Gln40Stop |
| PARK2 Arg42His |
| PARK2 Arg42Pro |
| PARK2 Asn52fs |
| PARK2 Asp53Stop |
| PARK2 Val56Glu |
| PARK2 Trp74fs |
| PARK2 Glu79StopPARK2 Ala82Glu |
| PARK2 Pro113fs / ex3 Δ40bp |
| PARK2 Pro133del |
| PARK2 Lys161Asn |
| PARK2 Gln171Stop |
| PARK2 Gly179fs |
| PARK2 Met192Leu |
| PARK2 Met192Val |
| PARK2 Lys211Asn |
| PARK2 Cys212Gly |
| PARK2 Cys212Tyr |
| PARK2 Arg234Gln |
| PARK2 Cys238fs |
| PARK2 Thr240Arg |
| PARK2 Thr240Met |
| PARK2 Val258Met |
| PARK2 Cys268Stop |
| PARK2 Arg275Trp |
| PARK2 Asp280Asn |
| PARK2 Leu283Pro |
| PARK2 Cys289Gly |
| PARK2 Ala291fs |
| PARK2 Gln311Stop |
| PARK2 Gln311His |
| PARK2 Cys323fs |
| PARK2 Val324fs |
| PARK2 Gly328Glu |
| PARK2 Arg334Cys |
| PARK2 Arg348fs |
| PARK2 Lys349fs |
| PARK2 Thr351Pro |
| PARK2 Gly359Asp |
| PARK2 Arg366Trp |
| PARK2 Arg392fs |
| PARK2 Glu395Stop |
| PARK2 Ala398Thr |
| PARK2 Glu409Stop |
| PARK2 Thr415Asn |
| PARK2 Asn428fs |
| PARK2 IVS11-3C>G |
| PARK2 Gly429Glu |
| PARK2 Gly430Asp |
| PARK2 Cys431Phe |
| PARK2 Glu444Gln |
| PARK2 Trp453Stop |
| PARK2 Asp460fs |

Pathogenic *PARK2* (NM\_013988 and NM\_004562) allele are defined according to OMIM (http://omim.org/) or the Parkinson Disease Mutation Database (http://www.molgen.vib-ua.be/PDMutDB/). Key: c., complementary DNA; del, deletion; dup, duplication; ex, exon; fs, frameshift; IVS, intervening sequence; trip, triplication; Δ40bp, 40bp deletion.



Supplementary Figure 1: Forest plot of the odds ratio (OR) of the Parkinson’s risk associated with heterozygous *PARK2* mutations using published studies that investigated biallelic *PARK2* mutations.

Boxes denote OR point estimates, their areas proportional to the inverse variance weight of the estimate. Horizontal lines represent 95% CIs. Vertical dashed line represents pooled OR point estimates. Key: CI, confidence intervals; *PARK2*, *Parkin* (NM\_013988 and NM\_004562); %, percentage.



Supplementary Figure 2: Forest plot of the odds ratio (OR) of the Parkinson’s (PD) risk associated with heterozygous *PARK2* mutations, excluding studies that consisted of predominantly early-onset PD cases.

Boxes denote OR point estimates, their areas proportional to the inverse variance weight of the estimate. Horizontal lines represent 95% CIs. Vertical dashed line represents pooled OR point estimates. Key: CI, confidence intervals; IPDGC, International Parkinson’s disease Genomics Consortium; *PARK2*, *Parkin* (NM\_013988 and NM\_004562); %, percentage; PPMI, Parkinson’s Progression Markers Initiative; Reseq, Resequencing; \*German samples only.



Supplementary Figure 3: Forest plot of the odds ratio (OR) of the Parkinson’s risk associated with heterozygous *PARK2* mutations, in studies that assessed biallelic mutation status and do not consist of predominantly early-onset cases.

Boxes denote OR point estimates, their areas proportional to the inverse variance weight of the estimate. Horizontal lines represent 95% CIs. Vertical dashed line represents pooled OR point estimates. Key: CI, confidence intervals; *PARK2*, *Parkin* (NM\_013988 and NM\_004562); %, percentage.



Supplementary Figure 4: Forest plot of the odds ratio (OR) of the Parkinson’s risk associated with heterozygous *PARK2* mutations, excluding p.R275W (c.823C>T, rs34424986).

Boxes denote OR point estimates, their areas proportional to the inverse variance weight of the estimate. Horizontal lines represent 95% CIs. Vertical dashed line represents pooled OR point estimates. Key: CI, confidence intervals; IPDGC, International Parkinson’s disease Genomics Consortium; p., protein reference sequence; *PARK2*, *Parkin* (NM\_013988 and NM\_004562); %, percentage; PPMI, Parkinson’s Progression Markers Initiative; Reseq, Resequencing; \*German samples only.



Supplementary Figure 5: Forest plot of the odds ratio (OR) of the Parkinson’s risk associated with heterozygous *PARK2* mutations, excluding p.R275W (c.823C>T, rs34424986), using published studies that investigated biallelic *PARK2* mutations.

Boxes denote OR point estimates, their areas proportional to the inverse variance weight of the estimate. Horizontal lines represent 95% CIs. Vertical dashed line represents pooled OR point estimates. Key: CI, confidence intervals; p., protein reference sequence; *PARK2*, *Parkin* (NM\_013988 and NM\_004562); %, percentage.